Apoptosis, the programmed and orderly cellular self-destruction process, plays a pivotal role in NASH development and its subsequent HCC transformations. Hepatocyte apoptosis is markedly amplified during NASH, not merely as a consequence but as a driving force exacerbating liver injury, fibrosis, inflammation, and tumorigenesis. Intrinsic mitochondrial dysfunction characterizes this apoptotic escalation. In animal models, nicotine exposure has been demonstrated to downregulate CDGSH iron-sulfur domain-containing protein 3 (CISD3), impairing mitochondrial efficiency and heightening oxidative stress. This pathological cascade exacerbates hepatocyte apoptosis, underscoring CISD3 as an emerging therapeutic focus in NAFLD.

Delving deeper into intrinsic apoptotic regulation reveals the critical influence of the BCL-2 protein family. Mitochondrial outer membrane permeabilization (MOMP), a decisive event in apoptosis initiation, is orchestrated by these proteins. Innovative pharmacological approaches, such as the acridone derivative A22, manipulate the BCL-2 gene promoter’s unique i-motif structure, elevating BCL-2 expression and attenuating hepatocyte apoptosis. This breakthrough represents the pioneering endeavor to exploit gene promoter architectures for therapeutic benefit in NASH. Similarly, the anti-apoptotic factor Mcl-1 is regulated via a feedback loop involving PNPT1, which modulates its mRNA stability under lipid-rich conditions, influencing mitochondrial permeability and apoptosis.

The extrinsic apoptotic pathway is equally compelling in the NAFLD/NASH arena. BID, a pro-apoptotic BH3-only protein, has garnered attention for its capacity to instigate mitochondrial apoptotic signals. Advanced siRNA frameworks targeting BID have achieved marked therapeutic effects, reducing fibrotic progression and inflammatory sequelae in murine models by diminishing key mitochondrial effectors BAX and BAK. Another notable target, receptor-interacting protein kinase 1 (RIPK1), governs the extrinsic apoptotic cell fate decision. Post-translational modifications such as deSUMOylation by SENP1 temper RIPK1 activity, mitigating cellular susceptibilities to apoptosis and positioning RIPK1 as a node for therapeutic intervention.

Central executors of apoptosis—caspases—are not exempt from focused modulation strategies. Pan-caspase inhibitors like emricasan demonstrated robust suppression of apoptotic enzymes caspase 3 and 7 in clinical trials, alongside favorable safety and tolerability profiles, underscoring their clinical potential. Emerging selective inhibitors targeting caspase 2 have also shown promise in restraining the transition from NAFLD to NASH, exemplifying the sophisticated refinement of apoptotic modulation.

Parallel to apoptosis, necroptosis—a regulated necrotic form of cell death characterized by plasma membrane rupture—has surfaced as a critical contributor to NAFLD pathophysiology. Necroptotic execution is mediated chiefly through the RIPK1/RIPK3/MLKL signaling axis. Pharmacological inhibitors of RIPK1, such as necrostatin-1s and RIPA-56, have demonstrated efficacy in attenuating inflammation, fibrosis, and liver injury in murine models. RIPK3 inhibition similarly reduces hepatocyte necroptosis, modulating oxidative stress and inflammatory cascades, though its role is complex, underscored by epigenetic silencing in primary hepatocytes and variable expression profiles in disease states. This nuanced relationship necessitates patient-specific considerations for therapeutic targeting.

The terminal effector MLKL further consolidates necroptotic signaling, and its deficiency confers protective effects against NAFLD progression by dampening lipid synthesis and inflammatory chemokine expression. Regulatory nodes extending beyond direct necroptotic mediators, such as ER stress-related proteins Derlin-1 and transcription factors like ATF3 and FOXO1, have emerged as influential in modulating necroptosis, opening additional therapeutic horizons. Intriguingly, necroptosis also manifests in non-parenchymal liver cells including natural killer cells and liver sinusoidal endothelial cells, highlighting the systemic nature of regulated cell death in NASH.

Pyroptosis, an inflammatory form of programmed cell death triggered by inflammasomes and punctuated by cell lysis and pro-inflammatory cytokine release, represents a escalating focus in NASH research. The NLRP3 inflammasome is a linchpin in this context, mediating hepatocyte pyroptosis and perpetuating fibrotic remodeling. Pharmacological inhibition of NLRP3 via molecules such as CY-09, MCC950, and others not only mitigates lipid accumulation but also temper inflammation and fibrosis. Beyond NLRP3, other inflammasomes like AIM2 have been implicated, activated by mitochondrial DNA, adding layers of regulatory complexity.

Gasdermin D (GSDMD), the executor pore-forming protein in pyroptosis, is notably elevated in NASH, with gene knockout models exhibiting decreased hepatic inflammation and fibrosis. Caspases, specifically caspase-11 and caspase-1, serve as upstream activators of pyroptosis via GSDMD cleavage and inflammasome modulation, and their inhibition has been linked to ameliorated disease markers. Beyond these direct effectors, regulatory pathways involving transcription factors (e.g., NR5A2, p-STAT3), pattern recognition receptors (TLR4), and non-coding RNAs intricately orchestrate pyroptotic responses, suggesting multifaceted opportunities for pharmacologic intervention.

The intersection of metabolic regulation and cell death is further highlighted by the application of antidiabetic drugs. SGLT2 inhibitors, GLP-1 receptor agonists, and others have demonstrated modulation of apoptosis and pyroptosis pathways, reflected in altered caspase activity and inflammasome components. However, differential effects, such as metformin’s facilitation of helicase-mediated pyroptosis in leptin-resistant models, underscore the necessity for nuanced understanding of drug actions within metabolic and hepatic contexts.

More recently, PANoptosis has been conceptualized as a coordinated cell death program integrating apoptosis, necroptosis, and pyroptosis, regulated through complex sensor and effector protein networks. Evidence implicates mitochondrial dysfunction as a key initializer, with herbal formulations like Si-Wu-Tang exhibiting protective effects by preserving mitochondrial integrity and suppressing mtDNA-mediated activation of PANoptotic pathways. Key proteins such as ZBP1 facilitate PANoptosome assembly, though their roles in NAFLD/NASH remain unexplored, representing critical frontiers for mechanistic and therapeutic research.

Ferroptosis, an iron-dependent form of regulated necrosis driven by lipid peroxidation, is increasingly recognized for its role in amplifying inflammation and hepatocyte death in steatohepatitis. Inhibitors of lipid peroxidation and iron chelators demonstrate potent hepatoprotective effects by interrupting ferroptotic cascades. Regulatory nodes such as ACSL4 and GPX4 are central, with therapeutic modulation via small molecules, transcription factors like ATF4, and epigenetic regulators providing promising strategies to attenuate ferroptosis. The crosstalk between ferroptosis and metabolic dysregulation is profound, evidenced by scaffold proteins like EFHD2 in immune cells influencing ferroptosis and fibrosis progression and the impact of gut microbiota and diet-derived metabolites on ferroptotic pathways.

Cuproptosis, a nascent form of regulated cell death induced by aberrant copper metabolism, has recently been associated with NAFLD progression and its malignant transformation. Bioinformatic analyses have unveiled multiple cuproptosis-related genes implicated in disease severity and prognosis. Proteins such as FDX1, CTR1, and LIAS surface as pivotal regulators, affecting mitochondrial function, oxidative stress, and lipid metabolic homeostasis. Furthermore, compounds influencing copper handling and ion transport show therapeutic promise, while insights from studies in hepatic stellate cells and hepatocellular carcinoma broaden the potential applicability of cuproptosis-targeted therapies within the liver disease spectrum.

Collectively, the intricate landscape of regulated cell death pathways influencing NAFLD/NASH pathogenesis and progression to HCC underscores an era ripe for innovative therapeutic development. Targeting apoptosis, necroptosis, pyroptosis, PANoptosis, ferroptosis, and cuproptosis offers convergent strategies to disrupt hepatocyte injury, fibrosis, and tumorigenesis. As the field advances through integrating mechanistic insights, emerging technologies such as single-cell analytics, gene editing, and nanodelivery platforms promise to refine precision medicine approaches. Ultimately, unraveling the interconnected networks governing hepatic cell fate decisions holds the key to mitigating the global health burden imposed by metabolic liver diseases.

Subject of Research: Targeting regulated cell death pathways in the progression of NAFLD/NASH and hepatocellular carcinoma

Article Title: Killing hepatocellular carcinoma in the NAFLD/NASH stage: a comprehensive perspective on targeting regulated cell death

Article References:

Xi, J., Lei, S., Chen, J. et al. Killing hepatocellular carcinoma in the NAFLD/NASH stage: a comprehensive perspective on targeting regulated cell death.
Cell Death Discov. 11, 281 (2025). https://doi.org/10.1038/s41420-025-02558-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02558-x

Cell death is a fundamental biological process critical for tissue homeostasis, development, and immune responses. Programmed cell death, predominantly apoptosis, is tightly regulated by the BCL-2 protein family, which governs mitochondrial membrane permeabilization—a decisive event dictating cell fate. Central to this regulation is the BH3 domain, a short amino acid sequence within pro-apoptotic proteins that interacts with anti-apoptotic members to unlock the cell’s intrinsic death machinery. The identification of BH3-like motifs within Nesprin-2 adds an unexpected dimension to this well-charted landscape, implicating a nuclear envelope-associated protein in the direct promotion of cell death pathways.

Nesprin-2, traditionally characterized for its structural role in linking the nucleus to the actin cytoskeleton via the linker of nucleoskeleton and cytoskeleton (LINC) complex, now emerges as more than a passive architectural scaffold. The study elucidates how the BH3-like sequences embedded within Nesprin-2 confer pro-apoptotic capabilities, effectively bridging nucleocytoplasmic communication with canonical mitochondrial apoptosis pathways. This finding provokes exciting questions about how nuclear envelope integrity and signaling are integrated with the decision-making processes governing cell death.

Through a series of intricate biochemical and cellular assays, Zohar and colleagues demonstrated that the BH3-like motifs in Nesprin-2 exhibit binding affinities akin to established BH3 domains, engaging with key regulators such as BCL-XL and MCL-1. This molecular interaction primes mitochondria for outer membrane permeabilization, culminating in the release of cytochrome c and downstream apoptotic events. Notably, the research delineated the spatial dynamics of Nesprin-2, showing that upon specific stress stimuli, conformational changes facilitate exposure of these BH3-like motifs, thereby instantaneously linking extracellular cues to apoptotic machinery.

The implications of this discovery are manifold. At a cellular level, it suggests that Nesprin-2 functions as an intrinsic sensor and mediator of death signals, potentially fine-tuning apoptosis in response to mechanical stress or nuclear envelope perturbations. Cells endure various mechanical forces and maintain nuclear shape via the LINC complex; the newfound apoptotic functionality of Nesprin-2 could serve as a fail-safe, eliminating damaged cells where mechanical integrity is compromised. This mechanotransduction-to-apoptosis axis may be particularly relevant in tissues subject to high mechanical strain, including muscle and cardiomyocytes.

Furthermore, the study sheds light on the potential involvement of Nesprin-2 in pathological states characterized by dysregulated apoptosis, such as cancer and neurodegeneration. Aberrant expression or mutation of Nesprin-2 could disrupt its BH3-like motif function, tipping the balance between cell survival and death, thus contributing to uncontrolled proliferation or defective clearance of damaged cells. This hypothesis opens avenues for exploring Nesprin-2 as a biomarker or therapeutic target, especially in cancers resistant to apoptosis-inducing agents.

Technically, the researchers employed advanced structural modeling techniques combined with mutagenesis to validate the functional relevance of the BH3-like motifs. High-resolution imaging further confirmed the translocation and conformational exposure of these motifs under apoptotic triggers. Functional knockdown experiments convincingly demonstrated attenuation of apoptosis when BH3-like sequences were mutated, underscoring their essential role. Such comprehensive methodological rigor strengthens confidence in the conclusion that Nesprin-2 intrinsically promotes programmed cell death.

In addition, the study provides insights into the interplay between nuclear architecture and cell death signaling, expanding the domain of apoptotic regulation beyond the mitochondria-centric perspective. The nuclear envelope, once thought to be a static barrier, is now recognized as an active signaling hub. Nesprin-2’s involvement introduces a paradigm wherein physical connections between the nucleus and cytoskeleton are leveraged to sense cellular health and initiate apoptosis when necessary. This mechanistic crosstalk may represent a critical checkpoint in maintaining cellular integrity and preventing oncogenic transformation.

Given the extensive expression of Nesprin-2 across various tissues, from epithelial to neuronal cells, these findings suggest broad physiological relevance. Future investigations may explore tissue-specific regulatory mechanisms of Nesprin-2’s BH3-like domains and how modulation of these motifs impacts developmental apoptosis and disease progression. Moreover, integration with other nuclear envelope proteins might reveal a complex network of pro- and anti-apoptotic signals, finely balancing cell survival in response to environmental and intracellular stresses.

From a translational viewpoint, this research invites the development of novel therapeutic strategies that harness or inhibit Nesprin-2’s BH3-like motif function. Small molecules or peptides mimicking these motifs could sensitize resistant cancer cells to apoptosis, while inhibitors could protect vulnerable cells in degenerative disorders. Such targeted modulation holds promise to refine current approaches in manipulating cell death with high specificity, minimizing off-target effects commonly associated with broader apoptotic regulators.

Additionally, the mechanistic nuance uncovered in this study underscores the importance of nuclear envelope integrity in cellular homeostasis. Pathologies such as laminopathies, where nuclear envelope defects are prominent, might also involve disrupted Nesprin-2-mediated apoptotic signaling. Deciphering these links could illuminate novel pathogenic pathways and suggest intervention points hitherto underappreciated in nuclear envelopathies.

In conclusion, the identification of BH3-like motifs within Nesprin-2 and their capacity to promote cell death is a seminal advancement that bridges structural nuclear biology with cell death regulation. This revelation compels us to reconsider the nuclear envelope as an active participant in apoptotic signaling rather than a mere barrier, highlighting a sophisticated integration of mechanical cues and molecular death programs. As the scientific community builds upon these findings, potentials for innovative therapeutics and deeper biological insights are poised to transform how we understand and manipulate programmed cell death.

Subject of Research: The pro-apoptotic role of Nesprin-2 via BH3-like motifs and its impact on programmed cell death mechanisms.

Article Title: Nesprin-2 contains BH3-like motifs that can promote cell death.

Article References:
Zohar, H., Kessel, A., Lindenboim, L. et al. Nesprin-2 contains BH3-like motifs that can promote cell death. Cell Death Discov. 11, 263 (2025). https://doi.org/10.1038/s41420-025-02534-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02534-5